TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07536724: First-in-man Trial to Assess the Safety, Performance and Clinical Benefit of the TRICENTO G2 Transcatheter Valve System for Tricuspid Regurgitation

Sponsor: Medira GmbH · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 20 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$6,905,600

Rescue Site Savings

+$4,548,400

Unlock Full NCT07536724 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07536724 Rescue Dossier →